La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

China Resources Double-Crane PharmaceuticalLtd Crescita futura

Future criteri di controllo 1/6

China Resources Double-Crane PharmaceuticalLtd prevede che gli utili e i ricavi cresceranno rispettivamente di 11.1% e 8.6% all'anno. Si prevede che l'EPS crescerà di 10.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.3% in 3 anni.

Informazioni chiave

13.8%

Tasso di crescita degli utili

13.4%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.9%
Tasso di crescita dei ricavi	9.7%
Rendimento futuro del capitale proprio	13.0%
Copertura analitica	Low
Ultimo aggiornamento	22 Aug 2024

Aggiornamenti recenti sulla crescita futura

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Recent updates

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Jul 16

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Mar 02

Previsioni di crescita degli utili e dei ricavi

SHSE:600062 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	13,386	2,037	N/A	2,383	2
12/31/2025	12,994	1,830	N/A	2,161	3
12/31/2024	11,714	1,633	N/A	1,884	3
3/31/2024	10,285	1,374	1,201	1,812	N/A
12/31/2023	10,222	1,333	1,026	1,631	N/A
9/30/2023	10,047	1,282	1,082	1,590	N/A
6/30/2023	9,983	1,223	922	1,404	N/A
3/31/2023	9,880	1,223	888	1,357	N/A
12/31/2022	9,625	1,180	890	1,416	N/A
9/30/2022	9,394	1,025	611	1,258	N/A
6/30/2022	9,392	1,078	720	1,337	N/A
3/31/2022	9,222	981	618	1,198	N/A
12/31/2021	9,112	936	849	1,341	N/A
9/30/2021	9,006	1,021	904	1,269	N/A
6/30/2021	8,987	1,046	964	1,328	N/A
3/31/2021	8,730	1,016	956	1,318	N/A
12/31/2020	8,504	1,005	1,012	1,360	N/A
9/30/2020	8,348	1,010	956	1,238	N/A
6/30/2020	8,663	971	1,068	1,323	N/A
3/31/2020	8,930	1,001	1,123	1,347	N/A
12/31/2019	9,381	1,055	1,198	1,440	N/A
9/30/2019	9,322	1,043	1,192	1,430	N/A
6/30/2019	9,003	1,024	1,195	1,428	N/A
3/31/2019	8,720	997	1,289	1,541	N/A
12/31/2018	8,225	969	1,240	1,469	N/A
9/30/2018	7,975	962	1,386	1,589	N/A
6/30/2018	7,434	905	1,211	1,406	N/A
3/31/2018	7,032	908	1,100	1,271	N/A
12/31/2017	6,422	843	N/A	1,187	N/A
9/30/2017	6,103	838	N/A	1,071	N/A
6/30/2017	5,725	801	N/A	1,107	N/A
3/31/2017	5,584	767	N/A	911	N/A
12/31/2016	5,495	714	N/A	771	N/A
9/30/2016	5,490	705	N/A	828	N/A
6/30/2016	5,414	684	N/A	775	N/A
3/31/2016	5,274	645	N/A	813	N/A
12/31/2015	5,138	661	N/A	701	N/A
9/30/2015	5,733	865	N/A	1,025	N/A
6/30/2015	5,562	832	N/A	1,016	N/A
3/31/2015	5,413	785	N/A	876	N/A
12/31/2014	5,153	737	N/A	929	N/A
9/30/2014	4,276	776	N/A	674	N/A
6/30/2014	5,184	845	N/A	539	N/A
3/31/2014	6,010	859	N/A	637	N/A
12/31/2013	6,835	871	N/A	546	N/A
9/30/2013	7,156	661	N/A	525	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 600062 ( 11.1% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 600062 ( 11.1% all'anno) cresceranno più lentamente rispetto al mercato CN ( 21.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 600062 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 600062 ( 8.6% all'anno) crescerà più lentamente rispetto al mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 600062 ( 8.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 600062 sarà basso tra 3 anni ( 12.3 %).

China Resources Double-Crane PharmaceuticalLtd Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 26% to CN¥24.32

Price target increased to CN¥19.26

Recent updates

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Dividend of CN¥0.26 announced

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.36 in 1Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Now 20% undervalued

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2022)

Price target increased by 26% to CN¥24.32

Investor sentiment improves as stock rises 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥19.26

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.30 in 2Q 2021)

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces an Equity Buyback for 23,500,000 shares, for CNY 431.7 million.

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.31 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.27 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥1.01 in FY 2019)

China Resources Double-Crane Pharmaceutical Plans to Invest in Zhejiang Biotech Firm

New 90-day low: CN¥11.83

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥11.90

New 90-day low: CN¥12.04

New 90-day low: CN¥12.51

Third quarter earnings released

New 90-day low: CN¥12.62

New 90-day low: CN¥12.77

Earnings released

New 90-day high - CN¥14.78

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita